Gilead Sciences Inc. (GILD)
-NasdaqGS 55.81 
0.33(0.59%) 25 May 04:00 SGT|After Hours
:
55.81 0.00 (0.00%) 25 May 04:54 SGT
| Prev Close: | 55.48 |
|---|
| Open: | 55.30 |
|---|
| Bid: | 54.50 x 100 |
|---|
| Ask: | 56.37 x 500 |
|---|
| 1y Target Est: | 64.54 |
|---|
| Beta: | 0.81 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 54.90 - 56.35 |
|---|
| 52wk Range: | 24.12 - 58.06 |
|---|
| Volume: | 8,745,685 |
|---|
| Avg Vol (3m): | 11,866,400 |
|---|
| Market Cap: | 85.13B |
|---|
| P/E (ttm): | 31.25 |
|---|
| EPS (ttm): | 1.79 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Biotechnology companiesAP(Sat, 06:03 SGT)
- Final Glance: Biotechnology companiesAP(Sat, 06:03 SGT)
- [video] Nasdaq Check: Valeant-Bausch & Lomb Deal?at CNBC(Sat, 01:30 SGT)
- Midday Glance: Biotechnology companiesAP(Sat, 01:17 SGT)
- Midday Glance: Biotechnology companiesAP(Sat, 01:17 SGT)
- Early Glance: Biotechnology companiesAP(Fri, 24 May)
- Gilead Sciences climbs to all-time highsAP(Sat, 4 May)
- Gilead Sciences 1Q income climbs 63 percentAP(Fri, 3 May)
- FDA rejects 2 HIV drugs from Gilead SciencesAP(Tue, 30 Apr)
- Moody's sees pick-up in pharmaceutical industry M&A in 2013Reuters(Tue, 23 Apr)
- Bayer Seeks Riociguat ApprovalZacks(Wed, 13 Feb)
- Gilead Closes YM Biosciences BuyoutZacks(Tue, 12 Feb)
- Gilead Beats Estimates in 4QZacks(Tue, 5 Feb)
- The Zacks Analyst Blog Highlights: Amgen, Celgene, Gilead Sciences, Vertex Pharmaceuticals and Nasdaq Biotechnology Index ETFZacks(Mon, 28 Jan)
- Actelion Drug Accepted for ReviewZacks(Wed, 19 Dec)
Key Statistics
| Forward P/E (1 yr): | 19.24 |
|---|
| P/S (ttm): | 8.50 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.97 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.49 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 1.06 |
|---|
Business Summary
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia.
View More